Christopher R. Shepard, PhD MBA, focuses on lifecycle inflection point (Phase 2) trial design, strategy, and sustainable financing in therapeutic drug development.
? Advised on over $1.5bn in investments and transactions in the life science sector spanning research, drug program development, combination product development, clinical trial design, personalized medicine and biomarkers, supply chain management, technology transfer, initial public offerings and innovative financing vehicles
? In Genentech's Commercial Group, work formed the best practices for a business area worth $5.6bn
? Advised institutional and activist shareholders with over $100bn under management on their controlling positions within small- and mid-cap biotechnology companies
? Work with the Releyent Corporation to develop a glucose-sensing contact lens technology won the company "Most Promising Life Science Company of the Year" from the Rice Alliance in 2011
? Private investor in life science start-ups such as ClearCount Medical Solutions (acquired by Stryker Corporation, 2014) and ALung Technologies
Previously, Dr. Shepard was a Visiting Scientist at the Massachusetts Institute of Technology in the Biological Engineering Group. He was a Principal Investigator for the Breast Cancer Research Program, part of the Congressionally Directed Medical Research Programs for the Department of Defense, and addressed the 8,000 scientists and physicians in attendance at the San Antonio Breast Cancer Symposium on his founding research in metastatic dyshesion and mesenchymal-epithelial reverting transitions (MErT). Dr. Shepard was awarded the Merit Award from the American Society of Investigative Pathology in 2007.
-
Specialties: Biotechnology, Drug Development, Risk Management of Drug Programs, Life Science Strategy